• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Multi-layered control of PD-L1 expression in Epstein-Barr virus-associated gastric cancer

    2020-07-28 07:14:58ChristosMiliotisFrankSlack

    Christos N. Miliotis, Frank J. Slack

    HMS Initiative for RNA Medicine, Department of Pathology, Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.

    Abstract Gastric cancer (GC) is the fifth most common cancer worldwide. In approximately 10% of GC cases, cancer cells show ubiquitous and monoclonal Epstein-Barr virus (EBV) infection. A significant feature of EBV-associated GC (EBVaGC) is high lymphocytic infiltration and high expression of immune checkpoint proteins, including programmed death-ligand 1 (PD-L1). This highlights EBVaGC as a strong candidate for immune checkpoint blockade therapy. Indeed, several recent studies have shown that EBV positivity in GC correlates with positive response to programmed cell death protein 1 (PD-1)/PD-L1 blockade therapy. Understanding the mechanisms that control PD-L1 expression in EBVaGC can indicate new predictive biomarkers for immunotherapy, as well as therapeutic targets for combination therapy. Various mechanisms have been implicated in PD-L1 expression regulation, including structural variations, post-transcriptional control, oncogenic activation of intrinsic signaling pathways, and increased sensitivity to extrinsic signals. This review provides the most recent updates on the multilayered control of PD-L1 expression in EBVaGC.

    Keywords: Epstein-Barr virus, gastric cancer, immunotherapy, programmed death-ligand 1

    INTRODUCTION

    Gastric cancer (GC) is the fifth most common and third most deadly cancer worldwide[1]. Due to the lack of early symptoms, patients are usually diagnosed with locally advanced or metastatic cancer, when conventional lines of therapy are less effective. The 5-year survival rate for GC in the United States varies by stage and ranges from 68% in patients with localized cancer to 5% in patients with distant metastases[2].

    Table 1. Immunological and molecular characteristics of GC molecular subtypes

    The majority of GCs (90%-95%) are adenocarcinomas[3]. The Cancer Genome Atlas (TCGA) recently undertook a comprehensive molecular characterization of hundreds of gastric adenocarcinomas and proposed classification of GC into four molecular subtypes: Epstein-Barr virus (EBV)-positive,microsatellite instability (MSI), chromosomal instability (CIN), and genomically stable (GS) subgroups[4].EBV-positive tumors are characterized by DNA hypermethylation, frequent phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations, and programmed cell death ligand 1(PD-L1)/programmed cell death ligand 2 (PD-L2)/Janus kinase 2 (JAK2) overexpression; MSI tumors have high mutation and DNA methylation rates; CIN tumors contain chromosomal alterations affecting mainly tyrosine kinase receptors; and fi nally, GS tumors are chromosomally stable and have a high frequency of cadherin 1 (CDH1) and Ras homolog family member A (RHOA) mutations [Table 1][4]. This review will focus on EBV-positive tumors.

    EBV is a double-stranded DNA virus that belongs to the herpesvirus family. An estimated 90% of the human population show signs of previous infection with EBV[7]. The virus is usually transmitted orally through saliva. Primary infection is most commonly asymptomatic, but it can lead to acute mononucleosis in a subset of the population, primarily adolescents and young adults[8]. Following primary infection, the virus establishes a lifelong latent infection in the host. EBV can remain latent in both lymphocytes and epithelial cells, where it expresses only a subset of its genes. Depending on which viral genes are expressed, latent EBV infection is typically classified into four latency programs, known as latency 0, I, II, and III [Table 2][7].

    In 1964, EBV was the first human virus to be associated with cancer, when it was discovered in Burkitt’s Lymphoma[9,10]. Since then, EBV has also been linked to other lymphomas, including Hodgkin lymphoma,diffuse large B-cell lymphoma (DLBCL), and Natural Killer/T-cell lymphomas (NK-T lymphomas)[11]. In addition, EBV has been associated with certain epithelial cancers, notably Nasopharyngeal Carcinoma(NPC) and GC. In both lymphoid and epithelial cancers, EBV persists in a latent state in infected cells[11].However, different EBV-associated cancers demonstrate different viral gene expression patterns [Table 2].

    Table 2. Viral genes expressed in each latency program

    In EBV-associated GC (EBVaGC), the virus expresses all latency I products, meaning EBV nuclear antigen 1 (EBNA1), Epstein-Barr encoding region small noncoding RNAs, BamHI A rightward transcripts (BARTs),and BART miRNAs, while around 50% of the cases also show Latent Membrane Protein 2A (LMP2A)expression, which is typically associated with latency II[12]. LMP1, another latency II protein, is typically not detected in EBVaGC samples[12-14]. There is strong geographical variation in the prevalence of EBVaGC but overall around 10% of gastric adenocarcinomas worldwide are classified as EBV-positive[15].

    In EBVaGC, the EBV genome is mainly maintained as a nuclear episome and cancer cells within the tumor show ubiquitous and monoclonal EBV infection[12,16]. The monoclonality of EBV infection suggests the clonal selection of virus-infected cells in early stages of cancer development. The role of EBV in gastric carcinogenesis is still under investigation, but EBV infection is thought to contribute to GC progression or maintenance, both directly through the activity of viral proteins or RNAs and indirectly through the induction of somatic alterations in the host genome and epigenome[17].

    PD-L1 EXPRESSION IN EBVAGC

    Multiple studies have shown that EBVaGC is commonly characterized by high lymphocytic infiltration in the tumor microenvironment, coupled with overexpression of immune-related genes, includingPD-L1(also known asCD274)[4,5,18]. PD-L1 is a glycoprotein, expressed by both cancer cells and stromal immune cells in the tumor, that engages the programmed cell death 1 (PD-1) receptor expressed on the surface of in filtrating cytotoxic T cells (CTLs)[19]. The interaction between PD-L1 and PD-1 leads to the inhibition of the tumor-in filtrating CTLs, preventing them from attacking and eliminating tumor cells.PD-L1is only one of multiple immune checkpoint genes that are known to be upregulated in EBV-positive compared to EBV-negative cancers.PD-L2, Lymphocyte activation gene-3 (LAG3), T cell immunoglobulin and mucin domain(Tim-3), Cluster of differentiation 80 (CD80), Cluster of differentiation 86 (CD86), and Indoleamine 2,3-dioxygenase 1 (IDO1) are also upregulated, butPD-L1has received particular interest because the PD-1/PD-L1 axis is the target of some recent breakthrough cancer therapies[20]. Monoclonal antibodies that block the interaction between PD-L1 and PD-1, thus restoring the ability of the immune system to surveil and attack the tumor, have shown promising results as therapeutic agents against multiple cancers, including non-small cell lung cancer and melanoma[19]. Recently, the Food and Drug Administration (FDA) approved pembrolizumab, a mAb targeting PD-1, as a third-line therapy for advanced gastric tumors that are positive for PD-L1 expression based on immunohistochemical (IHC) staining[21,22].

    The clinical efficacy and adverse effects of PD-1/PD-L1 therapy vary tremendously among patients. High expression of PD-L1 in the tumor has been implicated as a significant predictive biomarker for positive response to PD-1/PD-L1 therapy[23]. However, several clinical studies have demonstrated that some tumors with high PD-L1 expression do not respond to PD-1/PD-L1 therapy, while some tumors with moderate or low PD-L1 expression do show beneficial responses. This discrepancy could be attributed in part to the fact that direct determination of PD-L1 expression in the tumor, which is typically performed by IHC assays,has been proven to be difficult and inconsistent[24,25]. Understanding the molecular mechanisms that control PD-L1 expression in cancer may give rise to more accurate biomarkers for positive response to PD-1/PD-L1 therapy. In addition, regulators of PD-L1 expression could serve as targets for potential combination therapies.

    In a phase II clinical trial, Kimet al.[6]identified EBV-positivity and high mutational load as reliable and independent biomarkers for the clinical efficacy of pembrolizumab in GC patients and recommended considering pembrolizumab as an early therapeutic option for EBVaGC. MSI-high (MSI-H) tumors are characterized by high rates of somatic mutations, resulting in increased presentation of neoantigens and thus stimulation of anti-tumor immunity. As is the case in EBV-positive GCs, MSI-H tumors have high levels of tumor-infiltrating lymphocytes (TILs)[26]. The FDA has already approved the use of front-line pembrolizumab monotherapy in advanced MSI-H solid tumors of any origin, including stomach[27].

    EBVaGC appears to employ some common and some unique mechanisms for PD-L1 regulation. This review presents the most recent findings on PD-L1 regulation in EBVaGC and discusses some of the discrepancies in the literature, parallels with other EBV-associated cancers, and questions to be addressed in the future [Figure 1].

    EVOLUTIONARY PRESSURE FOR PD-L1 OVEREXPRESSION

    EBVaGC shows high levels of TILs and thus is under strong evolutionary pressure for the development of immune evasion strategies[4]. One such strategy is PD-L1 overexpression, which is evident in both cancer and stromal immune cells. It is speculated that the high immune activity in the EBVaGC microenvironment reflects the strong immunogenicity of EBV in the body. Up to 5% of the circulating CD8+T cells in EBV-infected individuals are believed to be reactive to lyticzor latent EBV antigens[28]. Indeed, several groups have detected expression of a subset of lytic genes in EBVaGC[29-31]. According to Borozanet al.[29], the lytic expression pattern detected in EBVaGC, which includes subsets of both early and late lytic proteins,does not indicate lytic, or abortive lytic, replication. However, the presentation of lytic viral antigens by infected cancer cells might be driving further immune activation. Camargoet al.[32]detected higher levels of circulating antibodies targeting both latent and lytic proteins in patients with EBV-positive compared to EBV-negative GCs, even though virtually all patients in the study were seropositive for antibodies against EBNA and the viral capsid. This further suggests that lytic proteins are expressed in EBVaGC and potentially contribute to the activation of the host immune response.

    SOMATIC STRUCTURAL VARIATIONS

    Somatic genomic alterations include short variations, such as single nucleotide substitutions and short insertions/deletions (indels), as well as long variations, also known as structural variations (SVs)[33].SVs affect large chromosomal regions (longer than 50 base-pairs) and include amplifications, deletions,inversions, and translocations[33]. Somatic changes occur continuously in the life of an individual and are usually repaired, but their accumulation over time can contribute to carcinogenesis[33]. EBVaGC only appears in a small percentage of EBV-infected individuals and typically long after primary EBV infection suggesting that somatic genomic changes are likely required for cancer development[34].

    Gene amplification

    Recent high-throughput sequencing studies have revealed different genomic alterations that lead to PD-L1 overexpression in EBVaGC. TCGA performed a somatic copy-number aberrations analysis in gastric adenocarcinoma samples and identified a frequent (15% of EBVaGC cases) somatic focal amplification at the chromosomal region 9p24.1, which includes the genesPD-L1,PD-L2, andJAK2[4]. This amplification was significantly more common in EBV-positive than EBV-negative tumors. Importantly, they showed that the 9p24.1 amplification correlated positively withPD-L1mRNA levels in the tumor[4]. Saitoet al.[35]detected 9p24.1 amplification events at a similar rate in a different EBVaGC cohort and demonstrated a direct association betweenPD-L1copy number and protein expression. Using fluorescence in-situ hybridization and IHC staining, they showed thatPD-L1genomic amplifications were specifically detected in cancer cells that showed high PD-L1 protein expression. Similar amplification patterns have been detected in other cancers, including hepatocellular carcinomas (HCC) and DLBCL[23,36].

    Figure 1. The mechanisms of PD-L1 regulation in EBVaGC discussed in this review. EBV: Epstein-Barr virus; EBVaGC: EBV-associated gastric cancer; PD-L1: programmed cell death ligand 1; IFNγ: interferon gamma; TNFα: tumor necrosis factor alpha; EBER: Epstein-Barr encoding region; JAK: Janus kinase; STAT: signal transducers and activators of transcription; IRF: interferon regulatory factor 1;EBNA1: EBV nuclear antigen 1; BART: BamHI A rightward transcripts; PIAS: protein inhibitor of activated STAT 3; IκBα: nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; NFκB: nuclear factor kappa-light-chain-enhancer of activated B cells; LMP2A: latent membrane protein 2A; PTEN: phosphatase and tensin homolog; PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PI3K: phosphoinositide 3-kinase; AKT: protein kinase B; ARID1A: AT-rich interaction domain 1A; mTOR:mammalian target of rapamycin; 3′-UTR: 3′ untranslated region; SV: structural variation; SNV: single nucleotide variation; BHRF1: BamHI fragment H rightward open reading frame 1. Created with BioRender.com

    Integration of EBV to the host genome

    In EBVaGC, the EBV genome is mostly maintained in the nucleus as a circular episome[16]. Some studies have also reported viral integration events, even though they are considered rare[4,37,38]. TCGA identified the presence of RNA sequencing (RNAseq) reads corresponding to a fusion between the hostPLGRKTgene and the EBV geneBHLF1in one EBVaGC sample (FP-7998-01)[4]. This is notable given that thePLGRKTlies within the 9p24.1 chromosomal region and is adjacent to thePD-L1locus. It was later shown in the same sample, that the amplified region containing the integrated EBV genome (Copy Number = 4) has a breakpoint in thePD-L13’ untranslated region (3’-UTR)[37]. Xuet al.[38]performed a genome-wide EBV integration analysis in multiple malignancies and identified that EBV integrates primarily in unstable chromosomal regions of the host genome. They identified EBV integration events in 25% (10/39) of the GC samples analyzed, with some of the integration breakpoints mapping close to known tumor suppressor genes[38]. None of their samples had integrated virus close toPD-L1,but studies with bigger EBVaGC sample sizes are necessary to identify the frequency and significance of viral integration in or close to thePD-L1locus. Viral integration in the host genome has been associated with increased PD-L1 expression in other virus-associated cancers. Caoet al.[20]identified integrated HPV genomes in thePD-L1orPD-L2loci in three cases from the TCGA Head and Neck Squamous Cell Carcinoma cohort and showed that these integration events correlated with elevated PD-L1 and PD-L2 expression.

    3’-UTR structural variations

    SVs in thePD-L13’-UTR have also been associated with increased PD-L1 expression in EBVaGC[34,37].Kataokaet al.[37]analyzed RNAseq data from all TCGA cancer types and searched for 3’-UTR disruptions inPD-L1. The authors identifiedPD-L13’-UTR truncations in 31/10,210 cancer cases and showed that they correlated with high PD-L1 expression. The highest frequency of 3’-UTR truncations was found in DLBCL(4/48) and GC (9/415), with a third of the GC samples (3/9) being EBV-positive. Therefore, around 10% of EBVaGC samples in TCGA were found to havePD-L13’-UTR SVs[34,37]. In a follow-up study, Kataokaet al.[34]analyzed samples from multiple EBV-associated lymphomas and found thatPD-L13’-UTR SVs were significantly more common in EBV-positive compared to EBV-negative lymphomas. They report thatPD-L13’-UTR genomic truncations in cell lines and mouse models promote PD-L1 overexpression and immune evasion, consistent with the patient data[37].

    POST-TRANSCRIPTIONAL REGULATION

    The 3’-UTR contains sequences or structural regions, called regulatory elements, that are important for the post-transcriptional regulation of a gene. These regulatory elements control binding to miRNAs and RNA-binding proteins (RBP), which in fluencem RNA stability, translation rate, and localization[39]. miRNAs are short non-coding RNAs that silence gene expression by binding to complementary sequences in the 3’-UTR of target mRNAs. miRNA-mRNA binding usually triggers mRNA degradation or blocks translation. The fact that 3’-UTR shortening has such a profound effect on PD-L1 expression in multiple cancers indicates that PD-L1 is under tight post-transcriptional control[37].

    3’-UTR short variations

    Mutations in the 3’-UTR have the capacity to remove existing or create new binding sites for miRNAs and RBPs. Some germline and somatic mutations in the 3’-UTR ofPD-L1have been shown to correlate with PD-L1 expression in gastric and other cancers[40-44]. Wuet al.[43]analyzed 728 GC samples and found that the AA and AG genotypes in rs2297136, a germline single nucleotide polymorphism (SNP) located in the 3’-UTR ofPD-L1, were associated with lower PD-L1 protein levels. They reported that the miRNAs miR-324-5p and miR-362 are predicted to bind to that region of thePD-L13’-UTR, but no validation experiments were pursued. Wanget al.[44]polymerase chain reaction (PCR)-amplified and sequenced the 3’-UTR ofPD-L1in hundreds of GC and matched normal samples and identified a frequent guanineto-cytosine somatic mutation that correlated with increased PD-L1 protein expression. It was shown that this mutation maps to a seed-binding region for miR-570 and it was proven experimentally that it increases PD-L1 expression by disrupting miR-570 binding[44]. To date, most studies looking atPD-L13’-UTR mutations have been low-throughput, with small sample sizes or targeted on speci fi c SNP locations.There has not been a comprehensive study looking at the frequency and effect of all possible somatic and germline variants in thePD-L13’-UTR in EBVaGC or other EBV-associated cancers. The fact that SVs in thePD-L13’-UTR appear to occur more frequently in EBV-positive than EBV-negative cancers raises the question of whether short variants in the 3’-UTR could be an alternative or parallel mechanism for PDL1 overexpression. Large-scale variant calling studies in gastric and other cancers, including the TCGA somatic mutation data, have mostly relied on whole exome sequencing data and exclude 3’-UTR sequences.This has created a gap in our understanding of 3’-UTR variations in cancer in general.

    Host miRNAs and RBPs

    Multiple miRNAs have been implicated in the control of PD-L1 expression in GC[45]. Some miRNAs,such as miR-152 and miR-200, target the 3’-UTR of PD-L1 directly. Other miRNAs, such as miR-19a and miR-19b, affect PD-L1 levels indirectly, by targeting signaling pathways or transcription factors that regulate PD-L1 expression[45-48].

    EBVaGC has been reported to exhibit a distinct host miRNA expression profile from other GC subtypes[4,49,50]. Differentially expressed miRNAs include ones that have been independently shown to target PD-L1, with the most notable example being miR-200[48]. miR-200 is a family of miRNAs found in two distinct genomic clusters and consists of miR-200a, miR-200b, miR-429, miR-200c, and miR-141[51].miR-200a, miR-200b, and miR-429 form a cluster on chromosome 1, while miR-200c and miR-141 form a cluster on chromosome 12. miR-200b, miR-200c and miR-429 share the same seed sequence, while miR-200a and miR-141 have a seed sequence that differs from the others by one nucleotide. ThePD-L13’-UTR contains one binding site for each seed-sharing functional cluster of miR-200 miRNAs and all miR-200a, b, and c have been shown to directly silence PD-L1 expression[48].

    The miR-200 family has been shown to be downregulated in EBV-positive compared to EBV-negative GC samples, as well as in EBV-negative GC cells following infection with recombinant EBV (rEBV)in vitro[52,53].Whether or how EBV latent proteins downregulate miR-200 remains unclear. Shinozakiet al.[53]reported that overexpression of any ofEBNA1,LMP2A, orBARF0(aBARTtranscript) in EBV-negative GC cells (MKN74 cell line) leads to miR-200a/b transcriptional repression, while overexpression of EBERs downregulates the mature miRNAs post-transcriptionally. The authors concluded that EBV latent proteins and RNAs act synergistically to downregulate miR-200. This is in contrast with a study by Marquitzet al.[52]on a different EBV-negative GC cell line, AGS. They reported that rEBV-infected AGS (AGS-EBV)cells showed consistent downregulation in some tumor suppressor miRNAs, including miR-200, when compared to the parental uninfected cells. However,EBNA1orLMP1overexpression in AGS did not affect the expression levels of miR-200 and most of the other EBV-downregulated miRNAs[52]. They speculate that EBV-mediated cellular miRNA downregulation might not be mediated by the latent viral proteins,but by viral miRNAs, through their effect on host transcription factors, or by EBERs[52]. Another possible mechanism of host miRNA downregulation in EBV-infected cells is methylation of their promoter sequences. EBV infection in GC cells has been shown to promote extensive DNA methylation, partly through the activity of the latent protein LMP2A, which induces DNA methyltransferases (DNMTs)[54,55].Indeed, the miR-200c promoter contains CpG islands that have been shown to be methylated by DNMT3a in GC[56].

    Research from our group described an EBV gene/host miRNA/PD-L1 regulation axis in B cell lymphomas,where the EBV protein EBNA2 induces PD-L1 expression by transcriptionally repressing miR-34a, a miRNA that downregulates PD-L1[57]. EBNA2 is a latency III-associated protein and thus is not expressed in GC. However, miR-34a has been shown to be downregulated in GC overall and to be transcriptionally repressed by EBNA1 in EBVaGC[58,59].

    ThePD-L13’-UTR contains multiple adenosine-uridine (AU)-rich elements (AREs) that are known to serve as binding sites for different RBPs[60]. In GC, the RBP tristetraprolin (TTP) has been shown to bind to AREs in thePD-L13’-UTR and to promote mRNA destabilization, leading to reduced PD-L1 expression[62].In addition, in NPC, the EBV latent protein LMP1 reduces TTP expression through extracellular-signalregulated kinase 1/2 (ERK1/2) activation[63]. Nonetheless, there has not been an association between EBV infection and TTP expression in GC.

    Viral miRNAs

    EBV expresses 25 precursor miRNAs (pre-miRNAs) and 44 mature miRNAs. Three pre-miRNAs are derived from the BamHI fragment H rightward open reading frame 1 (BHRF1) region of the viral genome,while the rest are derived from the BART region[64]. BART miRNAs are thought to play an important role in EBVaGC and are highly abundant, accounting for up to 15-20% of the total miRNA pool in some EBVaGC cell lines[65]. Some studies have demonstrated that xenografts of EBV-infected GC cell lines, including AGSEBV and SNU719 cells, in immunocompromised mice show up to 10- or 100-fold overexpression of BART miRNAs compared to their parental cell lines[66,67]. This suggests that BART miRNAs might be particularly important for cancer progressionin vivo. BART miRNAs are known to play a range of roles in GC,targeting host cell apoptosis, cell cycle, and metastasis[68,69]. Their role in immune evasion is less well studied in GC, although multiple immune-related functions have been attributed to BART miRNAs in other EBV-associated cancers[64].

    In contrast to BART miRNAs, which are expressed in all EBV latent stages, BHRF1 miRNAs are thought to be expressed only in latency III and lytic replication. BHRF1 miRNAs are commonly reported as barely detectable in GC tissues and cell lines[4,54,62]. However, Treeceet al.[49]analyzed miRNA expression in FFPE tissues from 78 cases of gastric adenocarcinoma, including 20 EBVaGCs, and reported that BHRF1-2-5p was signi fi cantly overexpressed in EBV-infectedvs.EBV-negative cancers, although to a lower extent than BART miRNAs. Marquitzet al.[52]also detected low expression of BHRF1 miRNAs in sequencing from EBV-infected GC cells (AGS-EBV). Both groups attributed the detection of BHRF1 miRNAs to possible low levels of viral replication. Given that several studies have reported the expression of a subset of lytic transcripts in EBVaGC, even in the absence of lytic replication, the level and importance of BHRF1 miRNA expression remain to be determined. In anin vitromodel of EBV-driven B-cell differentiation, BHRF1-2-5p was found to downregulate PD-L1[70]. The same study identified potential binding sites for some BART miRNAs in thePD-L13’-UTR, including BART19-3p, but overexpression of the miRNA did not appear to influence PD-L1 expression. Four BART miRNAs, BART2-5p, BART7-3p, BART14-3p, miR-BART22 were found to interact withPD-L1mRNA in a high-throughput photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) study in lymphoblastoid cell lines, but no validation experiments have been performed[71,72]. A recent study reported that miR-BART5-5p, which shares seed homology with the host miRNAs miR-18a-5p and miR-18b-5p,leads to signal transducers and activators of transcription 3 (STAT3)-dependent transcriptional PDL1 upregulation by targeting the STAT3 inhibitor Protein Inhibitor Of Activated STAT 3 (PIAS3)[73].

    INTRINSIC SIGNALING

    PD-L1 expression can be dysregulated by oncogenic activation of signaling pathways like the JAK/STAT,phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR),Mitogen-activated protein kinase/ERK kinase (MEK)/ERK, and Jun/Activator protein 1 (AP-1) pathways.These pathways act independently or synergistically to control PD-L1 expression, at the transcriptional,post-transcriptional, and post-translational stage[74-76]. Their importance in PD-L1 regulation tends to vary among different cancer types. The constitutive activation of an intrinsic signaling pathway in cancer is usually the result of mutations or SVs in genes of key components or regulators of the pathway. In the case of virus-associated cancers, viral proteins can also induce constitutive signaling in infected cells.

    Signaling activation by host gene mutations

    A frequently mutated gene in EBVaGC cancer isPIK3CA, which encodes a catalytic component of the PI3K kinase[4,77]. The most common variants inPIK3CAare associated with increased PI3K signaling activity[77]. The PI3K pathway is thought to regulate PD-L1 expression in a tissue-speci fi c manner. Loss of Phosphatase and tensin homolog (PTEN) leads to activation of the PI3K pathway and induction of PDL1 expression in gliomas and colorectal cancer[78,79]. In gliomas, Parsaet al.[79]showed that the PI3K/Akt/mTOR pathway increasesPD-L1mRNA translation through polysomal recruitment. In the case of GC,there is con fl icting evidence for the importance of the PI3K pathway in PD-L1 regulation. Supporting the importance of PI3K signaling in promoting PD-L1 expression, Kimet al.[80]showed that the PI3K inhibitor

    LY294002 reduced PD-L1 expression in three GC cell lines. In addition, Menyhártet al.[81]performed hierarchical clustering to determine the mutations that could best stratify TCGA GC patients based on PD-L1 expression. They showed that the mutation status ofPIK3CAserved as the best root node for the stratification, while mutations in other immune-related genes likeMEF2C,SLC11A1, andKIF15could help further refine it, suggesting potential interactions between these genes for the control of PD-L1 expression[81]. However, Mimuraet al.[82]performed experiments with a panel of GC cell lines and determined that the PI3K inhibitor wortmannin did not affect PD-L1 expression. Besides, Seoet al.[77]analyzed 112 EBV-positive GC samples and reported thatPIK3CAmutations did not show any correlation with PD-L1 expression or TIL abundance. Therefore, the importance ofPIK3CAmutations and PI3K signaling in the control of PD-L1 expression in GC and EBVaGC is still unclear, and may be dependent on interactions with other mutations and signaling pathways.

    Another gene that is commonly mutated in EBVaGC is AT-Rich Interaction Domain 1A (ARID1A),which encodes an important component of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex[4]. Mutations inARID1Aare usually loss-of-function mutations. Kimet al.[80]analyzed 273 GC samples and showed that ARID1A protein loss correlated with PD-L1 positivity (as defined by IHC staining), independently of EBV or MSI status. They also showed thatARID1Aknockdownin vitrodirectly leads to PD-L1 overexpression, through the activation of the PI3K/Akt pathway. To account for the variability in PD-L1 expression amongARID1A-mutated tumors, the authors looked for additional mutations that could be acting synergistically withARID1Amutations. They foundKRASmutations in the threeARID1A-mutated MSI-H tumors with the highest PD-L1 expression, while two other samples that harboredKRASbut notARID1Amutations did not show elevated PD-L1 levels. These data further suggest that PD-L1 expression is controlled by multiple oncogenic signaling pathways acting in coordination.

    Signaling activation by viral latent proteins

    The EBV latent membrane proteins (LMPs) are potent oncoproteins and are known to activate oncogenic signaling cascades in EBV-associated malignancies. In epithelial cancers, LMP2A has been found to regulate the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), PI3K/Akt, MEK/ERK,and transforming growth factor beta (TGFβ) pathways[83-86]. In GC speci fi cally, LMP2A has been reported to lead to constitutive NFκB activation by inhibiting the expression of the nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IκBα), which negatively regulates NFκB activity[83,84].The mechanism of IκBα downregulation appears to be unrelated to promoter methylation and remains to be determined. Independent studies have shown that NFκB promotes PD-L1 transcription in GC[87-89], but no direct association has been made between LMP2A, NFκB, and PD-L1. As mentioned above, LMP2A is also thought to be important for promoting the DNA hypermethylated state observed in EBVaGC.Hinoet al.[90]showed that LMP2A induces phosphorylation and activation of STAT3, which in turn leads to overexpression of DNMT1, thus changing the DNA methylation landscape of the cell. They showed that one of the targets of DNMT1 isPTEN, which encodes a negative regulator of the PI3K pathway. The hypermethylation of thePTENpromoter reduces PTEN expression and leads to overactivation of the PI3K pathway[90]. Interestingly, PTEN is also known to be directly targeted by miR-BART1 and BART7-3p in NPC[91,92]. Moonet al.[93]reported that the small interfering RNA (siRNA)-mediated knockdown of LMP2A did not affect PD-L1 expression in SNU719, an EBVaGC cell line. However, more studies with additional methods of manipulating LMP2A expression and activity are required to elucidate its role in PD-L1 regulation.

    INTERFERON GAMMA-INDUCIBLE PD-L1 EXPRESSION

    Multiple studies have reported that GC patients with higher levels of CD8+TILs also have higher PD-L1 expression[94-96]. This suggests that PD-L1 overexpression in EBVaGC is at least partly a result of the evolutionary pressure from the adaptive immune response acting against the cancer. When CD8+T cells are activated, such as through the recognition of neoantigens or viral antigens presented by cancer cells, they produce in fl ammatory cytokines like tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ)[97,98].IFNγ has been shown to induce PD-L1 expression in various cancers[99]. In GC, PD-L1 induction by IFNγ appears to occur mainly through the JAK/STAT/Interferon regulatory factor 1 (IRF1) signaling axis[82,100-102].The extent to which different cancer cells are responsive to IFNγ and the downstream effects of IFNγ exposure vary among cancer types and molecular subgroups within a cancer type.

    In TCGA and other GC cohorts, when EBVaGC samples are compared to EBV-negative ones, they demonstrate elevated IFNγ signatures, indicated by higher expression of IFNγ, JAK/STAT signaling components, and several IFNγ-induced genes[4,103]. In addition,in vitrostudies have shown that EBVaGC cell lines induce PD-L1 expression in response to IFNγ to a much higher extent than EBV-negative GC cell lines[93,104]. PD-L1 induction in response to IFNγ has also been shown to be significantly elevated in other EBV-associated epithelial malignancies, such as NPC[105]. In NPC, the viral protein LMP1 acts synergistically with IFNγ to induce PD-L1 expression through the activation of the JAK3/STAT3,NFκB, and AP-1 signaling pathways. In GC, EBNA1 has been shown to promote IFNγ-induced PD-L1 overexpression. Moonet al.[93]showed thatEBNA1knockdown in SNU719, an EBVaGC cell line, resulted in the transcriptional downregulation of JAK2.EBNA1knockdown also resulted in a small but signi fi cant reduction in constitutive and IFNγ-induced PD-L1 levels. However, ectopic EBNA1 expression in the EBV-negative GC cell line AGS did not affect constitutive or IFNγ-induced PD-L1 expression. In contrast,Suet al.[106]reported that AGS-EBV cells are more sensitive to IFNγ/TNFα treatment, showing higher downstream PD-L1 upregulation, than the uninfected parental cell line. This suggests that other viral factors, in addition to EBNA1, might be necessary for increasing IFNγ-induced PD-L1 expression in EBV-infected GC cells. Further studies are required to determine how EBNA1 and other viral or host factors promote increased IFNγ sensitivity and PD-L1 expression in EBVaGC.

    Nakayamaet al.[107]analyzed 43 EBVaGC samples and showed that the number of EBV genomes per cancer cell (EBV copy number) correlates positively with PD-L1 expression. Similarly, Stronget al.[31]performed cellular gene expression analysis on 12 EBV-positive and 20 EBV-negative TCGA GC samples and showed that, following hierarchical clustering, the 4 EBV-positive samples that had a much higher EBV coverage depth (in RNAseq data) than the rest of the EBV-positive samples formed a well-defined gene expression cluster. When they compared expression between “high” and “l(fā)ow” EBV GC samples, a large proportion of the genes that were upregulated in the “high” EBVaGC group were immune-related, including IFNγ,STAT1, IRF1, and multiple IFNγ-induced genes[31]. As the authors state, EBERs, which have been shown to induce IFNγ and TNFα production in peripheral blood mononuclear cellsin vitro, could be contributing to the elevated IFNγ signature found in “high” compared to “l(fā)ow” EBV GC samples[108].

    CONCLUSION

    Even though GC is declining in the United States, it still has one of the lowest 5-year survival rates of any cancer type[2]. This highlights the need for new therapeutic strategies, especially for metastatic cases that have the poorest prognosis and account for most of the new diagnoses every year. The molecular heterogeneity of GC correlates with the response rate to different therapies, indicating that different approaches should be considered for different molecular subgroups. The FDA recently approved pembrolizumab as second-line therapy for patients with advanced MSI-H tumors of any type, including GC[109]. In the last few years, several molecular and clinical studies present EBVaGC as another subgroup of GC that could benefit from early-line treatment with immune checkpoint inhibitors[6,107].

    In EBVaGC, high immune activation in the tumor microenvironment likely acts as a driving force for the selection of immune escape mechanisms such as PD-L1 overexpression. Different mechanisms act independently or synergistically to induce PD-L1 expression. These include somatic genomic modifications,oncogenic activation of intrinsic signaling pathways, increased sensitivity to PD-L1 inducing signals from the tumor microenvironment, and post-transcriptional control mechanisms. Overall, the regulation of PD-L1 expression in EBVaGC is poorly understood and further studies are necessary to explain how EBV and host factors contribute to it. Insight into the important genetic and epigenetic factors that control PD-L1 expression in EBVaGC and other cancers could reveal new biomarkers for positive response to immunotherapy, as well as novel therapeutic targets.

    DECLARATIONS

    Acknowledgments

    We especially appreciate Dr. Maria Mavrikaki, Allison Baker, Tanvi Saxena, and Jason Nomburg for their comments on this manuscript.

    Authors’ contributions

    Wrote the manuscript: Miliotis CN, Slack FJ

    Availability of data and materials

    Not applicable.

    Financial support and sponsorship

    Slack FJ acknowledges the NCI Outstanding Investigator Award (R35CA232105) and the support of the Ludwig Institute at Harvard and the V Foundation.

    Conflicts of interest

    Slack FJ discloses financial interests and SAB roles with Mira DX and MiRNA Therapeutics. The other author declares no competing financial interest.

    Ethical approval and consent to participate

    Not applicable.

    Consent for publication

    Not applicable.

    Copyright

    ? The Author(s) 2020.

    操出白浆在线播放| 久久久久久久久免费视频了| 久久99热这里只频精品6学生| 丁香六月欧美| 久热爱精品视频在线9| 欧美av亚洲av综合av国产av | 中国三级夫妇交换| 黑人猛操日本美女一级片| 亚洲综合精品二区| 9热在线视频观看99| 男女午夜视频在线观看| 男女床上黄色一级片免费看| 51午夜福利影视在线观看| 午夜老司机福利片| 我的亚洲天堂| 国产黄色视频一区二区在线观看| 女人高潮潮喷娇喘18禁视频| 国产在线视频一区二区| 国产精品久久久久久人妻精品电影 | 大片电影免费在线观看免费| 欧美乱码精品一区二区三区| 另类精品久久| 热99久久久久精品小说推荐| 国产成人午夜福利电影在线观看| videosex国产| 成人黄色视频免费在线看| 久久ye,这里只有精品| 国产精品久久久久久精品电影小说| 欧美日韩亚洲高清精品| 欧美老熟妇乱子伦牲交| 日韩人妻精品一区2区三区| 大码成人一级视频| 人妻人人澡人人爽人人| 日韩制服丝袜自拍偷拍| 啦啦啦 在线观看视频| 黄片无遮挡物在线观看| 大片电影免费在线观看免费| 欧美国产精品va在线观看不卡| 啦啦啦视频在线资源免费观看| 水蜜桃什么品种好| 日本91视频免费播放| 色94色欧美一区二区| 69精品国产乱码久久久| 久久久久久久久免费视频了| 麻豆精品久久久久久蜜桃| 波多野结衣av一区二区av| 性高湖久久久久久久久免费观看| 免费高清在线观看视频在线观看| 亚洲国产欧美在线一区| 亚洲婷婷狠狠爱综合网| 丝袜在线中文字幕| 亚洲成av片中文字幕在线观看| 久久免费观看电影| 日本猛色少妇xxxxx猛交久久| 一本久久精品| 亚洲精品国产av蜜桃| 在线精品无人区一区二区三| 麻豆av在线久日| 国产精品欧美亚洲77777| a 毛片基地| 男人添女人高潮全过程视频| 免费观看av网站的网址| 日韩大片免费观看网站| 咕卡用的链子| 亚洲少妇的诱惑av| 国产精品一区二区在线观看99| av免费观看日本| 久久热在线av| 一区二区三区激情视频| 一本一本久久a久久精品综合妖精| 老鸭窝网址在线观看| 美女扒开内裤让男人捅视频| 国产老妇伦熟女老妇高清| 一个人免费看片子| 男女之事视频高清在线观看 | 日韩大片免费观看网站| 人妻人人澡人人爽人人| 一个人免费看片子| 国产免费福利视频在线观看| 亚洲国产av影院在线观看| 丝袜美足系列| 日日啪夜夜爽| 国产熟女欧美一区二区| 欧美人与性动交α欧美精品济南到| 丰满迷人的少妇在线观看| 麻豆精品久久久久久蜜桃| 国产不卡av网站在线观看| 丝袜人妻中文字幕| 伦理电影免费视频| 在线免费观看不下载黄p国产| 男人添女人高潮全过程视频| 美女大奶头黄色视频| √禁漫天堂资源中文www| 老司机在亚洲福利影院| 成人午夜精彩视频在线观看| 男女下面插进去视频免费观看| 在线观看免费日韩欧美大片| 亚洲成国产人片在线观看| 一区二区三区四区激情视频| 狂野欧美激情性bbbbbb| 免费少妇av软件| 啦啦啦 在线观看视频| 这个男人来自地球电影免费观看 | 久久精品久久久久久久性| 99久久人妻综合| 日韩电影二区| 亚洲中文av在线| 亚洲激情五月婷婷啪啪| 午夜av观看不卡| 在线观看三级黄色| 久久国产亚洲av麻豆专区| 最近2019中文字幕mv第一页| 18禁观看日本| 蜜桃在线观看..| 亚洲七黄色美女视频| 亚洲天堂av无毛| 多毛熟女@视频| 我要看黄色一级片免费的| 十八禁高潮呻吟视频| 啦啦啦 在线观看视频| 国产极品天堂在线| 男女国产视频网站| 少妇人妻精品综合一区二区| 国产午夜精品一二区理论片| 1024视频免费在线观看| 丰满迷人的少妇在线观看| 悠悠久久av| 久久精品人人爽人人爽视色| 操美女的视频在线观看| 欧美国产精品va在线观看不卡| 国产免费又黄又爽又色| 高清黄色对白视频在线免费看| 在线观看三级黄色| 狂野欧美激情性bbbbbb| 亚洲在久久综合| 男人操女人黄网站| 大片免费播放器 马上看| 国产精品麻豆人妻色哟哟久久| 免费观看人在逋| 欧美中文综合在线视频| 日韩一区二区三区影片| 熟女av电影| 日本午夜av视频| 久久 成人 亚洲| videos熟女内射| 黄频高清免费视频| 免费av中文字幕在线| 天堂俺去俺来也www色官网| 久久鲁丝午夜福利片| av福利片在线| 丰满少妇做爰视频| 欧美av亚洲av综合av国产av | 亚洲熟女毛片儿| 大香蕉久久网| 性少妇av在线| 女性被躁到高潮视频| 1024香蕉在线观看| 婷婷色综合大香蕉| 日韩欧美精品免费久久| 日本欧美视频一区| 日韩一本色道免费dvd| 国产精品一区二区在线不卡| 狠狠精品人妻久久久久久综合| 亚洲成色77777| 操美女的视频在线观看| 欧美日韩精品网址| 亚洲国产精品999| 在线观看免费午夜福利视频| 亚洲国产欧美在线一区| 国产 精品1| 国产成人一区二区在线| 亚洲一卡2卡3卡4卡5卡精品中文| 91精品伊人久久大香线蕉| 国产日韩欧美亚洲二区| 欧美精品人与动牲交sv欧美| 亚洲情色 制服丝袜| 亚洲美女搞黄在线观看| 精品国产露脸久久av麻豆| 免费久久久久久久精品成人欧美视频| 麻豆乱淫一区二区| 精品少妇黑人巨大在线播放| 亚洲国产av影院在线观看| 咕卡用的链子| 少妇被粗大的猛进出69影院| 国产熟女午夜一区二区三区| 精品卡一卡二卡四卡免费| 久久精品熟女亚洲av麻豆精品| 男女边摸边吃奶| 高清不卡的av网站| 国产又爽黄色视频| 91国产中文字幕| 国产免费一区二区三区四区乱码| 精品一区二区三卡| 欧美日韩成人在线一区二区| 精品国产国语对白av| 日韩欧美一区视频在线观看| 波多野结衣一区麻豆| 国产在视频线精品| avwww免费| 制服诱惑二区| 日韩免费高清中文字幕av| kizo精华| 69精品国产乱码久久久| 久久精品亚洲熟妇少妇任你| 国产毛片在线视频| 精品一区二区免费观看| 日韩 亚洲 欧美在线| 精品人妻熟女毛片av久久网站| 亚洲国产av新网站| 亚洲国产精品成人久久小说| 国产成人一区二区在线| 菩萨蛮人人尽说江南好唐韦庄| 欧美国产精品va在线观看不卡| 国产一卡二卡三卡精品 | www日本在线高清视频| 亚洲国产精品999| 色吧在线观看| 亚洲熟女毛片儿| 美女脱内裤让男人舔精品视频| 午夜久久久在线观看| 欧美日韩亚洲高清精品| 欧美精品一区二区大全| 我的亚洲天堂| 久久国产精品男人的天堂亚洲| 国产极品天堂在线| 午夜福利视频精品| 日韩欧美一区视频在线观看| 亚洲美女视频黄频| 国产亚洲av高清不卡| 人人妻人人澡人人爽人人夜夜| 欧美日韩亚洲国产一区二区在线观看 | 咕卡用的链子| 欧美黄色片欧美黄色片| 日韩大片免费观看网站| 亚洲精品在线美女| 亚洲av日韩在线播放| 青春草亚洲视频在线观看| 18禁动态无遮挡网站| 一级毛片黄色毛片免费观看视频| 夫妻午夜视频| 亚洲美女搞黄在线观看| 女人久久www免费人成看片| 国产极品粉嫩免费观看在线| 97人妻天天添夜夜摸| 欧美最新免费一区二区三区| 亚洲欧洲日产国产| 国产欧美日韩一区二区三区在线| 在线看a的网站| 啦啦啦中文免费视频观看日本| 国产亚洲av片在线观看秒播厂| 视频在线观看一区二区三区| 欧美乱码精品一区二区三区| 国产精品二区激情视频| 大片电影免费在线观看免费| 国产深夜福利视频在线观看| 亚洲精品,欧美精品| 亚洲综合精品二区| 国产伦理片在线播放av一区| 免费不卡黄色视频| 免费看av在线观看网站| 男女免费视频国产| 日日爽夜夜爽网站| 国产午夜精品一二区理论片| 精品一区二区免费观看| 亚洲成人一二三区av| 最近最新中文字幕大全免费视频 | 天美传媒精品一区二区| 国产野战对白在线观看| av免费观看日本| 男人爽女人下面视频在线观看| 老汉色av国产亚洲站长工具| 男女边吃奶边做爰视频| 亚洲精品国产av蜜桃| 国产黄色免费在线视频| 无限看片的www在线观看| 在线天堂中文资源库| 欧美另类一区| 搡老岳熟女国产| 久久久久精品久久久久真实原创| 久久久久精品性色| 亚洲成人av在线免费| 欧美精品av麻豆av| 免费少妇av软件| 亚洲美女视频黄频| 亚洲精品国产区一区二| 久久精品国产亚洲av高清一级| 精品一区二区三区av网在线观看 | 制服丝袜香蕉在线| 一二三四中文在线观看免费高清| 亚洲人成网站在线观看播放| 性少妇av在线| 久久久久久久大尺度免费视频| 欧美在线一区亚洲| 人妻人人澡人人爽人人| av有码第一页| 人人澡人人妻人| 日韩欧美一区视频在线观看| 久久久久视频综合| 999精品在线视频| 又大又爽又粗| 国产 精品1| 肉色欧美久久久久久久蜜桃| 一区二区三区四区激情视频| 国产av一区二区精品久久| 十分钟在线观看高清视频www| 婷婷成人精品国产| 男女边摸边吃奶| 女性被躁到高潮视频| 99国产综合亚洲精品| 丁香六月欧美| 99re6热这里在线精品视频| www.熟女人妻精品国产| 巨乳人妻的诱惑在线观看| 亚洲伊人久久精品综合| 狠狠精品人妻久久久久久综合| 国产午夜精品一二区理论片| 亚洲欧洲国产日韩| 亚洲三区欧美一区| 亚洲精品自拍成人| 亚洲四区av| 国产精品.久久久| 亚洲精品国产色婷婷电影| 青春草视频在线免费观看| 久久久久精品久久久久真实原创| 国产亚洲一区二区精品| 亚洲av欧美aⅴ国产| 亚洲欧美清纯卡通| 亚洲av电影在线进入| 国产99久久九九免费精品| h视频一区二区三区| 色吧在线观看| 亚洲伊人色综图| 99精品久久久久人妻精品| 免费看av在线观看网站| 亚洲激情五月婷婷啪啪| www日本在线高清视频| 欧美日韩亚洲综合一区二区三区_| 伦理电影免费视频| 精品视频人人做人人爽| 久久久久视频综合| 亚洲精品一区蜜桃| 国产精品成人在线| 秋霞在线观看毛片| 免费观看人在逋| 一级毛片我不卡| 日本黄色日本黄色录像| 青青草视频在线视频观看| 成人午夜精彩视频在线观看| 精品久久蜜臀av无| 亚洲国产毛片av蜜桃av| 亚洲av男天堂| 晚上一个人看的免费电影| 只有这里有精品99| 久热爱精品视频在线9| 伊人亚洲综合成人网| 国产老妇伦熟女老妇高清| 丝袜美腿诱惑在线| 久久精品国产综合久久久| 亚洲成色77777| av国产精品久久久久影院| 亚洲在久久综合| 久久午夜综合久久蜜桃| 国产一卡二卡三卡精品 | 伊人久久大香线蕉亚洲五| 最黄视频免费看| 女人被躁到高潮嗷嗷叫费观| 如日韩欧美国产精品一区二区三区| 少妇 在线观看| 一级片免费观看大全| 午夜激情av网站| 老鸭窝网址在线观看| 9热在线视频观看99| 欧美在线一区亚洲| 97人妻天天添夜夜摸| 老鸭窝网址在线观看| 水蜜桃什么品种好| 纵有疾风起免费观看全集完整版| 老司机深夜福利视频在线观看 | 高清视频免费观看一区二区| 国产精品女同一区二区软件| 亚洲欧美成人精品一区二区| 欧美中文综合在线视频| 少妇被粗大的猛进出69影院| 国产视频首页在线观看| 少妇被粗大的猛进出69影院| 国产人伦9x9x在线观看| 国产伦理片在线播放av一区| 久久午夜综合久久蜜桃| 深夜精品福利| av国产精品久久久久影院| 国产欧美亚洲国产| 美女福利国产在线| www.av在线官网国产| 精品一区二区三区av网在线观看 | xxx大片免费视频| 在线观看一区二区三区激情| 色综合欧美亚洲国产小说| 巨乳人妻的诱惑在线观看| 欧美日韩亚洲国产一区二区在线观看 | 亚洲av综合色区一区| 午夜av观看不卡| 欧美日韩亚洲高清精品| 亚洲欧美成人综合另类久久久| 晚上一个人看的免费电影| 欧美日韩视频精品一区| 飞空精品影院首页| 精品国产一区二区久久| 人人妻,人人澡人人爽秒播 | 99热网站在线观看| 亚洲少妇的诱惑av| 久久久久视频综合| 一区福利在线观看| 伦理电影免费视频| 欧美黑人欧美精品刺激| 久久97久久精品| 精品酒店卫生间| 一二三四中文在线观看免费高清| av有码第一页| 午夜91福利影院| 99国产综合亚洲精品| 99久国产av精品国产电影| 美女脱内裤让男人舔精品视频| 亚洲欧美一区二区三区久久| 欧美日韩综合久久久久久| 亚洲国产欧美网| 精品国产乱码久久久久久男人| 亚洲精品国产av成人精品| 你懂的网址亚洲精品在线观看| 最近手机中文字幕大全| 免费观看av网站的网址| 777久久人妻少妇嫩草av网站| 天天操日日干夜夜撸| 国产精品99久久99久久久不卡 | 久久久久久人人人人人| 性少妇av在线| 国产xxxxx性猛交| 欧美国产精品一级二级三级| 深夜精品福利| 毛片一级片免费看久久久久| 成人亚洲精品一区在线观看| av电影中文网址| 国产成人精品久久久久久| 久久精品亚洲熟妇少妇任你| 亚洲精品自拍成人| 韩国高清视频一区二区三区| 亚洲天堂av无毛| 99久久人妻综合| 七月丁香在线播放| 亚洲国产毛片av蜜桃av| 久久久精品94久久精品| 80岁老熟妇乱子伦牲交| 日韩成人av中文字幕在线观看| 亚洲精品美女久久av网站| 色播在线永久视频| 亚洲av日韩在线播放| 国产在视频线精品| 欧美xxⅹ黑人| 久久久久国产精品人妻一区二区| 两性夫妻黄色片| 亚洲精品国产av蜜桃| 日韩大片免费观看网站| 国产精品国产av在线观看| 日本爱情动作片www.在线观看| 国产一区二区激情短视频 | 制服人妻中文乱码| 黄色一级大片看看| 欧美国产精品va在线观看不卡| 亚洲av欧美aⅴ国产| 久久久久久免费高清国产稀缺| 99香蕉大伊视频| 新久久久久国产一级毛片| 免费久久久久久久精品成人欧美视频| 1024香蕉在线观看| 热re99久久国产66热| 久久精品国产亚洲av高清一级| 国产 精品1| 成人黄色视频免费在线看| 亚洲少妇的诱惑av| 欧美另类一区| 美女高潮到喷水免费观看| 亚洲自偷自拍图片 自拍| 亚洲精品视频女| 如何舔出高潮| 精品午夜福利在线看| 欧美老熟妇乱子伦牲交| 9191精品国产免费久久| 色精品久久人妻99蜜桃| 中文字幕亚洲精品专区| 最新在线观看一区二区三区 | 久久久精品免费免费高清| 久久热在线av| 99国产综合亚洲精品| 国产精品免费视频内射| 在线观看免费午夜福利视频| 国产免费又黄又爽又色| 久久午夜综合久久蜜桃| 天天添夜夜摸| 九色亚洲精品在线播放| 最黄视频免费看| 一个人免费看片子| 欧美久久黑人一区二区| 久久国产精品大桥未久av| 国产精品一区二区精品视频观看| 成人黄色视频免费在线看| 在线观看人妻少妇| 国产片内射在线| 亚洲av日韩精品久久久久久密 | 国产亚洲一区二区精品| 亚洲av成人精品一二三区| 国产精品久久久av美女十八| 久久综合国产亚洲精品| 久久精品人人爽人人爽视色| 97人妻天天添夜夜摸| 少妇被粗大猛烈的视频| 男女无遮挡免费网站观看| 黄色怎么调成土黄色| 一级毛片黄色毛片免费观看视频| 一级a爱视频在线免费观看| 亚洲色图 男人天堂 中文字幕| 18禁观看日本| 亚洲欧洲日产国产| 在线天堂中文资源库| 老司机影院成人| 欧美亚洲 丝袜 人妻 在线| 人人妻,人人澡人人爽秒播 | 我的亚洲天堂| 欧美xxⅹ黑人| 丝袜在线中文字幕| 午夜激情久久久久久久| 99re6热这里在线精品视频| 我要看黄色一级片免费的| 91国产中文字幕| 久久久国产欧美日韩av| av天堂久久9| 最近中文字幕2019免费版| 国产 精品1| 免费在线观看黄色视频的| 一区福利在线观看| 美女福利国产在线| 视频在线观看一区二区三区| 自拍欧美九色日韩亚洲蝌蚪91| 久久毛片免费看一区二区三区| 中文字幕av电影在线播放| 国产成人精品久久二区二区91 | 欧美精品一区二区大全| 丝袜在线中文字幕| 熟女少妇亚洲综合色aaa.| 国产探花极品一区二区| 2021少妇久久久久久久久久久| 亚洲一区二区三区欧美精品| 亚洲图色成人| 国产男女内射视频| 性高湖久久久久久久久免费观看| 热99国产精品久久久久久7| 免费观看a级毛片全部| 亚洲国产毛片av蜜桃av| 看免费av毛片| 交换朋友夫妻互换小说| 嫩草影视91久久| 国产亚洲最大av| 国产免费现黄频在线看| 99热全是精品| 亚洲一卡2卡3卡4卡5卡精品中文| 日本欧美视频一区| 日日爽夜夜爽网站| 一级,二级,三级黄色视频| 高清在线视频一区二区三区| 中文字幕最新亚洲高清| 中文字幕另类日韩欧美亚洲嫩草| a级毛片在线看网站| 亚洲专区中文字幕在线 | 午夜福利一区二区在线看| 热re99久久国产66热| 国产极品天堂在线| 亚洲少妇的诱惑av| 国产成人av激情在线播放| 国产成人精品久久二区二区91 | 最新的欧美精品一区二区| 久久久国产欧美日韩av| 看免费av毛片| 久久免费观看电影| 极品少妇高潮喷水抽搐| 两个人看的免费小视频| 成人毛片60女人毛片免费| 女的被弄到高潮叫床怎么办| 国产亚洲欧美精品永久| 久久久国产精品麻豆| 国产精品国产三级国产专区5o| 性少妇av在线| 99国产精品免费福利视频| 美女国产高潮福利片在线看| 久久这里只有精品19| 亚洲精品一二三| 热99国产精品久久久久久7| 久久久久精品久久久久真实原创| 欧美黑人精品巨大| netflix在线观看网站| 青草久久国产| 久久婷婷青草| 一区二区三区乱码不卡18| 亚洲精品日韩在线中文字幕| www.自偷自拍.com| 国产一区二区 视频在线| 国产福利在线免费观看视频| 久久人人97超碰香蕉20202| 亚洲国产精品一区三区| 亚洲av日韩在线播放| 三上悠亚av全集在线观看| 国产精品欧美亚洲77777| 精品国产乱码久久久久久男人| 在线免费观看不下载黄p国产| 如日韩欧美国产精品一区二区三区| 国产爽快片一区二区三区| 伦理电影免费视频| 男女免费视频国产|